Abstract P3-13-10: The maintenance treatment after xeloda contained regimens with xeloda or endocrine for HR positive and HER2 negative MBC patients

Abstract

Abstract Objective To discuss the optimizing selection of maintenance treatment after xeloda-contained chemotherapy regimen being applicated in HER-2 negative, HR positive relapsing metastatic breast cancer(MBC) patients, and contrast the curative effect of maintenance treatment with xeloda or endocrine. Methods 119 patients with HER-2 negative, HR positive were enrolled during 2009-2013.All patients taking the xeloda contained chemotherapy regimens to obtain CR,PR or SD were randomly divided into group A(65 cases, maintenance capecitabine therapy 800-1000mg/ m2 bid, orally, Days 1 ∼ 14, q3w)and group B(54 cases, a switch to maintenance endocrine therapy). Endpoints include overall survival (OS) and progression-free survival (PFS). Results The ages, menopausal status, number of metastases and treatment line numbers had no statistical differences between two groups, and the p value of two therapy co-operative groups was 0.002. There were 37 patients(56.9%)using TX and 28(43.1%)using NX in therapy co-operative group A. There were 39 patients (72.2%)using TX, 9(16.7%)using NX and 6(6%) using regimen containing xeloda in therapy co-operative group B. Progression-free survival was 8 months in patients who follow by xeloda and 12 months in those who follow by endocrine (p<0.01).Conclusion Endocrine therapy after xeloda-contained chemotherapy regimen tend to be more effective than single xeloda therapy for patients with HER-2 negative, HR positive. This results request to be verified by advanced OS data, which was needed to in-depth study in clinic and explore relevant biological indicators. Citation Format: Zefei Jiang, Fan Qi, Shaohua Zhang, Li Bian, Tao Wang, Lei Li. The maintenance treatment after xeloda contained regimens with xeloda or endocrine for HR positive and HER2 negative MBC patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-13-10.